Choroidal Melanoma

1. Comprehensive Introduction & Overview

Choroidal melanoma represents the most prevalent primary intraocular malignancy in adults. Originating from the melanocytes located within the choroid—the highly vascularized layer of the eye situated between the retina and the sclera—this neoplasm presents significant clinical challenges due to its potential for hematogenous metastasis, most commonly to the liver.

While rare compared to cutaneous melanoma, choroidal melanoma carries a distinct biological profile. It is a diagnosis that requires rapid multidisciplinary intervention, involving ophthalmologists, ocular oncologists, radiation oncologists, and medical oncologists. Early detection is the single most critical factor in preserving vision and preventing systemic disease progression.

Epidemiological Snapshot

• Incidence: Approximately 5–6 cases per million people annually in the United States.
• Demographics: Predominantly affects Caucasian populations; incidence increases with age, peaking in the sixth and seventh decades.
• Biological Behavior: Unlike cutaneous melanoma, which is strongly associated with UV exposure, the etiology of choroidal melanoma is more complex, involving genetic predispositions and specific somatic mutations.

2. Deep-Dive: Mechanisms and Pathophysiology

The transformation of a benign choroidal nevus into a malignant melanoma is a multi-step molecular process. Understanding these mechanisms is essential for modern clinical management and prognostication.

Etiology and Genetic Drivers

The pathogenesis of choroidal melanoma is defined by a distinct sequence of driver mutations. Unlike the BRAF mutations common in skin cancers, choroidal melanomas are characterized by:
* GNAQ and GNA11 Mutations: Present in >80% of cases, these mutations activate the MAPK and YAP signaling pathways, driving uncontrolled cellular proliferation.
* BAP1 Mutations: Located on chromosome 3, the loss of BAP1 is strongly associated with a high risk of metastatic disease.
* SF3B1 and EIF1AX Mutations: These mutations generally correlate with a more favorable, intermediate, or low-risk metastatic profile.

Pathophysiological Progression

The tumor begins as a localized proliferation of melanocytes. As it expands, it disrupts the Retinal Pigment Epithelium (RPE), leading to secondary retinal detachment. The tumor is highly vascular; it recruits blood supply through angiogenesis, which simultaneously provides the primary route for systemic dissemination.

3. Clinical Indications, Staging, and Presentation

Standard Clinical Presentation

Patients often remain asymptomatic in the early stages, particularly if the tumor is located peripherally. Symptoms typically emerge as the tumor grows or affects the macula:
* Blurred vision or scotoma: Resulting from macular involvement or subretinal fluid.
* Photopsia: Flashes of light caused by retinal irritation.
* Metamorphopsia: Distortion of visual lines.
* Incidental finding: Often discovered during routine dilated fundus examinations.

The Collaborative Ocular Melanoma Study (COMS) Staging

Clinical staging is determined primarily by the tumor's basal diameter and height (thickness).

Differential Diagnosis

It is imperative to distinguish choroidal melanoma from benign or reactive processes:
1. Choroidal Nevus: Usually smaller, lacks subretinal fluid, and remains stable over time.
2. Choroidal Hemangioma: Typically orange-red, lacks the "hollow" ultrasound appearance of melanoma.
3. Metastatic Carcinoma: Often multifocal and bilateral, distinct from the usually solitary melanoma.
4. Choroidal Osteoma: Calcified, bone-like appearance on imaging.

4. Key Diagnostic Tests and Workup

Diagnostic accuracy is built on the "TFSOM" (To Find Small Ocular Melanomas) criteria.

• Fundus Photography: To document baseline size and pigment characteristics.
• B-Scan Ultrasonography: The gold standard for measuring tumor height and internal reflectivity (melanomas typically show low internal reflectivity).
• Optical Coherence Tomography (OCT): Essential for evaluating subretinal fluid and RPE integrity.
• Fluorescein Angiography (FA): Reveals "double circulation"—the presence of both retinal and intrinsic tumor vessels.
• Fine Needle Aspiration Biopsy (FNAB): Increasingly used for genetic profiling (e.g., GEP testing) to determine metastatic risk.

5. Management Strategies

Treatment is dictated by the tumor size, location, and the patient's visual status.

Conservative/Local Therapies

• Plaque Brachytherapy: The application of a radioactive isotope (e.g., Iodine-125) directly to the sclera over the tumor site. This is the standard of care for small to medium-sized tumors.
• Charged Particle Irradiation (Proton Beam): Used for tumors located near the optic nerve or macula where plaque placement is challenging.
• Transpupillary Thermotherapy (TTT): Rarely used today due to high recurrence rates, reserved for specific thin tumors.

Surgical Interventions

• Enucleation: Surgical removal of the eye. Indicated for very large tumors, cases with extraocular extension, or when there is no potential for useful vision.
• Local Resection (Iridocyclectomy/Choroidectomy): Highly specialized, rarely performed surgical removal of the tumor while sparing the globe.

6. Risks, Side Effects, and Long-Term Prognosis

Treatment-Related Side Effects

Radiation therapy, while effective at controlling the primary tumor, carries long-term ocular risks:
* Radiation Retinopathy: Progressive vascular damage leading to ischemia and vision loss.
* Radiation Optic Neuropathy: Damage to the optic nerve.
* Secondary Cataracts: Clouding of the lens due to radiation exposure.
* Neovascular Glaucoma: A severe complication of ischemic retinopathy.

Long-Term Prognosis

Survival is tied to the risk of metastasis. Approximately 50% of patients will develop metastatic disease within 10–15 years, primarily in the liver.
* Low Risk (Class 1A): Low gene expression profile; excellent survival rates.
* High Risk (Class 2): High gene expression profile; significant probability of systemic metastasis.

Monitoring Protocol: Because of the high risk of liver metastasis, patients must undergo biannual or annual liver function tests (LFTs) and abdominal imaging (MRI or PET/CT).

7. Frequently Asked Questions (FAQ)

1. Is choroidal melanoma related to sun exposure?

Unlike skin melanoma, there is no strong, direct epidemiological link between UV exposure and choroidal melanoma. It is considered a stochastic genetic event.

2. Is it hereditary?

Most cases are sporadic. However, BAP1-tumor predisposition syndrome can lead to a familial clustering of uveal melanoma and other cancers.

3. Can I still see after treatment?

Yes. Many patients retain useful vision, especially if the tumor is treated early and is located away from the fovea or optic nerve.

4. Why is the liver the primary site of metastasis?

The eye’s venous drainage eventually leads to the portal circulation, which favors the liver as the first "filter" for metastatic cells.

5. What is "GEP" testing?

Gene Expression Profiling (GEP) is a molecular test performed on tumor tissue to categorize the risk of metastasis into Class 1 (low risk) or Class 2 (high risk).

6. Can a nevus turn into a melanoma?

Yes, "transformation" is possible. This is why stable nevi are monitored annually with imaging.

7. What are the symptoms of metastatic spread?

Metastasis is often asymptomatic until late. Symptoms may include unintentional weight loss, abdominal pain, jaundice, or fatigue.

8. Is enucleation always necessary for large tumors?

Not always, but for very large tumors that would require radiation doses causing blindness and pain, enucleation is often the safest oncological choice.

9. How often should I have follow-up exams?

Initially, every 3–6 months. If stable, the frequency may decrease to every 6–12 months, but lifelong surveillance is mandatory.

10. Are there new systemic therapies for metastatic disease?

Yes. Tebentafusp (a bispecific T-cell engager) has recently been approved for HLA-A*02:01 positive patients with metastatic uveal melanoma, representing a major breakthrough in treatment.

8. Conclusion

Choroidal melanoma remains a complex, sight-threatening, and life-threatening condition. The shift toward personalized medicine, specifically through genetic profiling and targeted systemic therapies like Tebentafusp, has revolutionized the management landscape. For the clinician, the priority remains early detection through rigorous screening and the utilization of multimodal diagnostic imaging. For the patient, the journey requires a committed partnership with a specialized ocular oncology team to balance local tumor control with the preservation of quality of life and long-term systemic health.